-+ 0.00%
-+ 0.00%
-+ 0.00%

Alkermes says Phase 3 REVITALYZ trial shows LUMRYZ improves idiopathic hypersomnia sleepiness

PUBT·05/12/2026 11:01:52
Listen to the news
Alkermes says Phase 3 REVITALYZ trial shows LUMRYZ improves idiopathic hypersomnia sleepiness
  • Alkermes reported positive topline results from REVITALYZ, a Phase 3 study of once-nightly LUMRYZ in adults with idiopathic hypersomnia.
  • Trial met primary endpoint, showing meaningful improvement versus placebo in daytime sleepiness and patient-reported disease severity, with safety consistent with established LUMRYZ profile.
  • Detailed results will be presented at a future medical meeting.
  • Company plans to file a supplemental New Drug Application with FDA by end of 2026, though it cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028 under a prior settlement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202605120700BIZWIRE_USPR_____20260512_BW566395) on May 12, 2026, and is solely responsible for the information contained therein.